Drug Trial Radar · NCT07516951
A Study to Find an Efficacious and Safe Dose of CHF10067 (Zampilimab) in Participants With Idiopathic Pulmonary Fibrosis
Last checked: Nov 19, 2026Latest source record: Oct 16, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
240
Planned (sponsor's estimate)
Start
Jul 8, 2026
Primary completion
Jun 27, 2028
Study completion Jun 27, 2028
Sponsor
- Lead sponsor
- Chiesi Farmaceutici S.p.A.Industry
- Sponsor type
- Industry
- First posted
- Apr 8, 2026
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 40 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to evaluate the efficacy, safety, and tolerability at Week 24 of 2 doses of CHF10067 (zampilimab) in participants with idiopathic pulmonary fibrosis (IPF). It is a phase IIb, multicentre, randomised, double-blind, placebo-controlled, three-arm parallel-group study. A total of 240 participants with IPF (Idiomatic Pulmonary Fibrosis) will be randomised in approximately 150 investigational sites in North and Latin America, Europe, Asia, and Oceania.
Conditions
- Idiopathic Pulmonary Fibrosis
Interventions
CHF10067Drug
Dose 1 CHF10067 Intravenous (IV) infusion
CHF10067Drug
Dose 2 CHF10067 IV infusion
PlaceboOther
Placebo IV infusion
Primary outcomes
What the sponsor says the trial is designed to measure.
- Primary Outcome Measure: Absolute change from baseline in ppFVC (percent predicted forced vital capacity) at Week 24.Time frame: At Week 24
Locations
19 sites in 4 countries. Site status is shown where the registry gives one.
SEC Clinical Research LLC
Dothan, Alabama · Recruiting
Pasadena Center for Medical Research, Inc
St. Petersburg, Florida · Recruiting
Hannibal Regional Healthcare System, Inc.
Hannibal, Missouri · Recruiting
Clinical Research of Rock Hill
Rock Hill, South Carolina · Recruiting
Tennessee Comprehensive Lung and Sleep Center
Hendersonville, Tennessee · Recruiting
Premier Pulmonary Critical Care and Sleep Medicine, PA
Denison, Texas · Recruiting
PHI University Clinic of Pulmonology and Allergology
Skopje, North Macedonia · Recruiting
Soon Chun Hyang University Bucheon Hospital
Bucheon-si, South Korea · Recruiting
Inje University Busan Paik Hospital
Busan, South Korea · Recruiting
Inje University Haeundae Paik Hospital
Busan, South Korea · Recruiting
Chonnam National University Hospital
Gwangju, South Korea · Recruiting
Kyung Hee University Hospital
Seoul, South Korea · Recruiting
Korea University Anam Hospital
Seoul, South Korea · Recruiting
The Catholic University of Korea, Eunpyeong St. Mary's Hospital
Seoul, South Korea · Recruiting
Asan Medical Center
Seoul, South Korea · Recruiting
Seoul Metropolitan Government-Seoul National University Boramae Medical Center
Seoul, South Korea · Recruiting
Ajou University Hospital
Suwon, South Korea · Recruiting
Royal Papworth Hospital NHS Foundation Trust
Cambridge, United Kingdom · Recruiting
Royal Devon and Exeter Hospital - Royal Devon University Healthcare NHS Foundation Trust
Exeter, United Kingdom · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.